Beta
361193

LASER PHOTOCOAGULATION VERSUS INTRAVITREAL ANTI VEGF AGENTS FOR TREATMENT OF RETINOPATHY OF PREMATURITY

Article

Last updated: 28 Dec 2024

Subjects

-

Tags

-

Abstract

Background: Early birth and various oxygen techniques can cause retinopathy of prematurity
(ROP), a widespread childhood visual problem. An aggressive ROP (A-ROP) differs from normal
progression. Diode laser replaced cryotherapy. Laser treatment is customary but limited, prompting
anti-VEGF research. BEAT-ROP aids anti-VEGF.
Aim: Compare efficacy and safety of laser
photocoagulation with intravitreal anti-VEGF agents for ROP.
Methods: Retrospective study at
Qena university hospital, adhering to Helsinki Declaration. Participants had ROP type 1 or AROP, treated with anti-VEGF or laser within 72 hours (or 24 hours for A-ROP) between 2021
and 2024 at Qena University, followed for ≥6 months. ICROP criteria guided diagnosis and
classification. Treatment decision involved parental consultation; unfit patients for general anesthesia
received anti-VEGF. Patients anticipated to have poor adherence to follow up received antiVEGF. Post-treatment follow-ups evaluated efficacy, with cycloplegic refraction at 6 months.
Outcome measures included regression, reactivation, and retinal detachment.
Results: Significant
differences observed between Anti-VEGF and Laser groups in Zone-I ROP and APROP
parameters. No significant variation in sex distribution, gestational age (GA), birth weight, or followup duration in Zone-I. In Zone-II, significant differences in GA, birth weight, and follow-up duration.
Anti-VEGF demonstrated superior outcomes in initial regression, reactivation, and retinal detachment.
Conclusion: Anti-VEGF therapy, notably Ranibizumab, outperforms laser photocoagulation
for ROP treatment in aggressive forms in Zone I. This appears to show better initial regression,
lesser reactivation, and lower retinal detachment. Anti-VEGF therapy, and laser photocoagulation
for ROP treatment in Zone II appears to show comparable initial regression and retinal detachment but laser show lesser reactivation than Anti-VEGF therapy. Research in clinical practice
is needed.

DOI

10.21608/ejco.2024.361193

Keywords

laser photocoagulation, Intravitreal anti-VEGF agents, retinopathy of prematurity, Ocular therapy

Authors

First Name

Aldghaimy,

Last Name

A.

MiddleName

-

Affiliation

Ophthalmology dept., Faculty of Medicine, South Valley, Univ., Egypt,

Email

-

City

-

Orcid

-

Volume

7

Article Issue

1

Related Issue

48557

Issue Date

2024-06-01

Receive Date

2024-01-29

Publish Date

2024-06-01

Page Start

87

Page End

95

Print ISSN

2537-0502

Online ISSN

2537-0944

Link

https://ejco.journals.ekb.eg/article_361193.html

Detail API

https://ejco.journals.ekb.eg/service?article_code=361193

Order

11

Type

Original articles: include clinical trials, interventional research, Basic researches and clinically relevant laboratory investigations

Type Code

1,824

Publication Type

Journal

Publication Title

Egyptian Journal of Clinical Ophthalmology

Publication Link

https://ejco.journals.ekb.eg/

MainTitle

LASER PHOTOCOAGULATION VERSUS INTRAVITREAL ANTI VEGF AGENTS FOR TREATMENT OF RETINOPATHY OF PREMATURITY

Details

Type

Article

Created At

28 Dec 2024